Hiroyuki Tsutsumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hiroyuki Tsutsumi has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
Tsukasa Hori
Department of Pediatrics Sapporo Medical University School of Medicine Sapporo Japan
11 shared publications- Yuko Yoto
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
11 shared publications Naoki Hatakeyama
Department of Pediatrics, Asahikawa Medical University Hospital, Asahikawa, Japan
10 shared publicationsNobuhiro Suzuki
Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo, Japan
10 shared publicationsKeita Igarashi
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
6 shared publicationsMasaki Yamamoto
Department of Pediatrics Sapporo Medical University School of Medicine Sapporo Japan
6 shared publications
Latest Publications
- 12 November 2021
- Published by Wiley in Pediatrics International
- Vol. 64 (1)
Children’s decision making in cancer therapy: A long‐term observational study
Background: The survival rate of children with cancer has increased substantially in recent years. Shared decision making (i.e., the ability of children with cancer to express their will and share it with medical personnel) has become a particularly important issue. The nature and developmental processes of children’s decision making in hospital should be understood. There is, however, a lack of research in this area. Methods: From January 2016 to March 2018, we conducted a longitudinal qualitative observational study, within the context of medical anthropology, in a hospital pediatric ward in Japan. We investigated the nature and development of decision making among seven children aged 5–12 years with hematologic cancers. We recorded their everyday behaviors, interactions, narratives, and events in the ward. The recording was conducted systematically and it was analyzed thematically using both variable‐oriented and process‐oriented modes to assess causal relationships between phenomena. Results: The thematic analysis identified three thematic scenes in which children developed their will regarding cancer treatment: (1) adjusting to hospital life; (2) forming friendships with other children; and (3) communicating with medical personnel. Sharing information, building trusting relationships, and sharing treatment goals with medical personnel were identified as forms of children’s participation in medical decision making. Through cultivated friendships, children’s peer groups were sources of resilience and strength in overcoming difficulties in hospital life. Conclusions: The development of children’s decision making in a pediatric oncology ward was based on various rich human relationships. Such relationships should be promoted to improve shared decision making substantially.
- 12 November 2021
- Published by Wiley in Pediatrics International
- Vol. 64 (1)
Children’s decision making in cancer therapy: A long‐term observational study
Background: The survival rate of children with cancer has increased substantially in recent years. Shared decision making (i.e., the ability of children with cancer to express their will and share it with medical personnel) has become a particularly important issue. The nature and developmental processes of children’s decision making in hospital should be understood. There is, however, a lack of research in this area. Methods: From January 2016 to March 2018, we conducted a longitudinal qualitative observational study, within the context of medical anthropology, in a hospital pediatric ward in Japan. We investigated the nature and development of decision making among seven children aged 5–12 years with hematologic cancers. We recorded their everyday behaviors, interactions, narratives, and events in the ward. The recording was conducted systematically and it was analyzed thematically using both variable‐oriented and process‐oriented modes to assess causal relationships between phenomena. Results: The thematic analysis identified three thematic scenes in which children developed their will regarding cancer treatment: (1) adjusting to hospital life; (2) forming friendships with other children; and (3) communicating with medical personnel. Sharing information, building trusting relationships, and sharing treatment goals with medical personnel were identified as forms of children’s participation in medical decision making. Through cultivated friendships, children’s peer groups were sources of resilience and strength in overcoming difficulties in hospital life. Conclusions: The development of children’s decision making in a pediatric oncology ward was based on various rich human relationships. Such relationships should be promoted to improve shared decision making substantially.
- 19 January 2020
- Published by Wiley in Pediatrics International
- Vol. 62 (5) , 569-575
Rotavirus genotype and Vesikari score of outpatients in Japan in the vaccine era
Background: Group A rotaviruses (RVs) are a major cause of severe gastroenteritis among infants and young children. In Japan, RV vaccines were introduced in 2011, leading to a reduction in severe gastroenteritis cases. Studies are required to assess the effectiveness of the vaccines and their effect on the prevalence of RV genotypes.Methods: Fecal samples were collected from outpatients with RV gastroenteritis in a pediatric clinic in Sapporo, Japan, from 2010 to 2016. GPI genotypes were determined using reverse‐transcription polymerase chain reaction. Clinical information and immunization records were obtained from outpatients after 2013. GPI genotypes and clinical features were compared between patients with and without a RV vaccine history.Results: In total, 270 cases were genotyped. G1P[8]I1 (Wa‐like G1P[8]) strains were dominant from 2010 to 2012. G1P[8]I2 (DS‐1‐like G1P[8]) strains appeared in 2012 and dominated in 2013 to 2015. G2P[4]I2 and G9P[8]I1 strains increased every 3 years (G2P[4]I2: 2011 and 2014, G9P[8]I1: 2010, 2013 and 2016). After the 2013 season, 137 cases were collected, 24 of which were vaccinated. Cases requiring drip infusion were fewer in the vaccination group than in the non‐vaccination group (16.7% vs 52.2%). No patients required hospitalization in the vaccination group compared with 10.6% in the non‐vaccination group. A severe Vesikari score was less common in the vaccination group than in the non‐vaccination group (33.3% vs 78.8%). There was no significant difference in the GPI genotype distribution between the two groups.Conclusion: Rotaviruses vaccine effectiveness, regardless of GPI genotype, was confirmed in terms of alleviation of disease severity.
- 19 January 2020
- Published by Wiley in Pediatrics International
- Vol. 62 (5) , 569-575
Rotavirus genotype and Vesikari score of outpatients in Japan in the vaccine era
Background: Group A rotaviruses (RVs) are a major cause of severe gastroenteritis among infants and young children. In Japan, RV vaccines were introduced in 2011, leading to a reduction in severe gastroenteritis cases. Studies are required to assess the effectiveness of the vaccines and their effect on the prevalence of RV genotypes.Methods: Fecal samples were collected from outpatients with RV gastroenteritis in a pediatric clinic in Sapporo, Japan, from 2010 to 2016. GPI genotypes were determined using reverse‐transcription polymerase chain reaction. Clinical information and immunization records were obtained from outpatients after 2013. GPI genotypes and clinical features were compared between patients with and without a RV vaccine history.Results: In total, 270 cases were genotyped. G1P[8]I1 (Wa‐like G1P[8]) strains were dominant from 2010 to 2012. G1P[8]I2 (DS‐1‐like G1P[8]) strains appeared in 2012 and dominated in 2013 to 2015. G2P[4]I2 and G9P[8]I1 strains increased every 3 years (G2P[4]I2: 2011 and 2014, G9P[8]I1: 2010, 2013 and 2016). After the 2013 season, 137 cases were collected, 24 of which were vaccinated. Cases requiring drip infusion were fewer in the vaccination group than in the non‐vaccination group (16.7% vs 52.2%). No patients required hospitalization in the vaccination group compared with 10.6% in the non‐vaccination group. A severe Vesikari score was less common in the vaccination group than in the non‐vaccination group (33.3% vs 78.8%). There was no significant difference in the GPI genotype distribution between the two groups.Conclusion: Rotaviruses vaccine effectiveness, regardless of GPI genotype, was confirmed in terms of alleviation of disease severity.
- 5 September 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (9) , 882-884
Anemia associated with increased hepcidin in two children with Castleman disease
- 5 September 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (9) , 882-884
Anemia associated with increased hepcidin in two children with Castleman disease
- 14 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (6) , 547-552
Long‐term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) frequently have HHV‐6 reactivation typically during the early phase following HSCT. The long‐term clinical complications and prognosis, however, remain unclear.Methods: Between September 2010 and October 2012, whole blood samples from 105 patients collected weekly from prior to 6 weeks after HSCT underwent multiplex polymerase chain reaction (PCR) to screen for viral DNA, followed by real‐time PCR for quantitative estimation. In 48 patients, only HHV‐6 was detected in at least one sample. In 30 patients, no viral DNA was detected. Long‐term clinical records were reviewed in March 2016. All 48 HHV‐6‐positive patients, and 24 patients in whom no viral DNA detected, were followed up.Results: Median maximum HHV‐6 DNA load in the blood of the HHV‐6 reactivation group (n = 48) was 11 800 copies/μg peripheral blood leukocyte DNA (range, 52–310 000 000). Hemophagocytic syndrome (HPS) was diagnosed in two subjects with HHV‐6 reactivation. Acute graft‐versus‐host disease (GVHD) developed more frequently in patients with HHV‐6 reactivation than in patients without viral reactivation (P = 0.002), but there was no difference in incidence of chronic GVHD. There was no difference in engraftment of neutrophils and platelets between groups. There was also no difference in overall survival between groups. Onset of HPS, however, was associated with lower overall survival (P = 0.009).Conclusions: Human herpesvirus 6 reactivation was associated with acute GVHD, but not with chronic GVHD, engraftment or overall survival. Onset of HPS, however, predicts lower overall survival.
- 14 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (6) , 547-552
Long‐term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) frequently have HHV‐6 reactivation typically during the early phase following HSCT. The long‐term clinical complications and prognosis, however, remain unclear.Methods: Between September 2010 and October 2012, whole blood samples from 105 patients collected weekly from prior to 6 weeks after HSCT underwent multiplex polymerase chain reaction (PCR) to screen for viral DNA, followed by real‐time PCR for quantitative estimation. In 48 patients, only HHV‐6 was detected in at least one sample. In 30 patients, no viral DNA was detected. Long‐term clinical records were reviewed in March 2016. All 48 HHV‐6‐positive patients, and 24 patients in whom no viral DNA detected, were followed up.Results: Median maximum HHV‐6 DNA load in the blood of the HHV‐6 reactivation group (n = 48) was 11 800 copies/μg peripheral blood leukocyte DNA (range, 52–310 000 000). Hemophagocytic syndrome (HPS) was diagnosed in two subjects with HHV‐6 reactivation. Acute graft‐versus‐host disease (GVHD) developed more frequently in patients with HHV‐6 reactivation than in patients without viral reactivation (P = 0.002), but there was no difference in incidence of chronic GVHD. There was no difference in engraftment of neutrophils and platelets between groups. There was also no difference in overall survival between groups. Onset of HPS, however, was associated with lower overall survival (P = 0.009).Conclusions: Human herpesvirus 6 reactivation was associated with acute GVHD, but not with chronic GVHD, engraftment or overall survival. Onset of HPS, however, predicts lower overall survival.
- 2 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (4) , 357-361
Predictive factors of response toIVIGin pediatric immune thrombocytopenic purpura
Background: Immune thrombocytopenic purpura (ITP) is commonly treated with i.v. immunoglobulin (IVIG).Methods: We retrospectively evaluated whether pretreatment clinical and laboratory finding could predict the short‐ and long‐term response toIVIG.Results: Short‐term response was estimated by platelet count 2 weeks afterIVIG, and long‐term response was assessed on thrombocytopenia‐free survival (TFS).TFSwas defined as the probability of survival without treatment failure after initialIVIG, such as relapse, requirement for additional therapeutic interventions, or progressing to chronicITP. Seventy‐six patients with newly diagnosedITPwho were initially treated withIVIGwere evaluated. Fifty‐three patients (69.7%) were determined as responders at 2 weeks afterIVIG. On multivariate analysis, age ≥23 months (P= 0.020) and platelet count 9/L (P= 0.018) were considered to be unfavorable factors for short‐term response. Cumulative proportion of long‐term (1 year) good prognosis was estimated at 53.0% (95%CI: 40.8–65.2). On multivariate analysis of unfavorable factors for long‐term response, age ≥23 months (P= 0.020) was the only significant factor.Conclusions: For new‐onsetITPin patients aged >2 years, corticosteroid therapy in addition toIVIGmay be considered as the initial treatment.
- 2 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (4) , 357-361
Predictive factors of response toIVIGin pediatric immune thrombocytopenic purpura
Background: Immune thrombocytopenic purpura (ITP) is commonly treated with i.v. immunoglobulin (IVIG).Methods: We retrospectively evaluated whether pretreatment clinical and laboratory finding could predict the short‐ and long‐term response toIVIG.Results: Short‐term response was estimated by platelet count 2 weeks afterIVIG, and long‐term response was assessed on thrombocytopenia‐free survival (TFS).TFSwas defined as the probability of survival without treatment failure after initialIVIG, such as relapse, requirement for additional therapeutic interventions, or progressing to chronicITP. Seventy‐six patients with newly diagnosedITPwho were initially treated withIVIGwere evaluated. Fifty‐three patients (69.7%) were determined as responders at 2 weeks afterIVIG. On multivariate analysis, age ≥23 months (P= 0.020) and platelet count 9/L (P= 0.018) were considered to be unfavorable factors for short‐term response. Cumulative proportion of long‐term (1 year) good prognosis was estimated at 53.0% (95%CI: 40.8–65.2). On multivariate analysis of unfavorable factors for long‐term response, age ≥23 months (P= 0.020) was the only significant factor.Conclusions: For new‐onsetITPin patients aged >2 years, corticosteroid therapy in addition toIVIGmay be considered as the initial treatment.
- Open Access
- 21 January 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (1) , 85-87
Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia
- 21 January 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (1) , 85-87
Open AccessResponse to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia
- Open Access
- 16 January 2018
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 4 (1) , 5
Early Detection and Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Missed by Newborn Screening Using Tandem Mass Spectrometry
Citrullinemia is the earliest identifiable biochemical abnormality in neonates with intrahepatic cholestasis due to a citrin deficiency (NICCD) and it has been included in newborn screening panels using tandem mass spectrometry. However, only one neonate was positive among 600,000 infants born in Sapporo city and Hokkaido, Japan between 2006 and 2017. We investigated 12 neonates with NICCD who were initially considered normal in newborn mass screening (NBS) by tandem mass spectrometry, but were later diagnosed with NICCD by DNA tests. Using their initial NBS data, we examined citrulline concentrations and ratios of citrulline to total amino acids. Although their citrulline values exceeded the mean of the normal neonates and 80% of them surpassed +3 SD (standard deviation), all were below the cutoff of 40 nmol/mL. The ratios of citrulline to total amino acids significantly elevated in patients with NICCD compared to the control. By evaluating two indicators simultaneously, we could select about 80% of patients with missed NICCD. Introducing an estimated index comprising citrulline values and citrulline to total amino acid ratios could assure NICCD detection by NBS.
- 16 January 2018
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 4 (1) , 5
Open AccessEarly Detection and Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Missed by Newborn Screening Using Tandem Mass Spectrometry
Citrullinemia is the earliest identifiable biochemical abnormality in neonates with intrahepatic cholestasis due to a citrin deficiency (NICCD) and it has been included in newborn screening panels using tandem mass spectrometry. However, only one neonate was positive among 600,000 infants born in Sapporo city and Hokkaido, Japan between 2006 and 2017. We investigated 12 neonates with NICCD who were initially considered normal in newborn mass screening (NBS) by tandem mass spectrometry, but were later diagnosed with NICCD by DNA tests. Using their initial NBS data, we examined citrulline concentrations and ratios of citrulline to total amino acids. Although their citrulline values exceeded the mean of the normal neonates and 80% of them surpassed +3 SD (standard deviation), all were below the cutoff of 40 nmol/mL. The ratios of citrulline to total amino acids significantly elevated in patients with NICCD compared to the control. By evaluating two indicators simultaneously, we could select about 80% of patients with missed NICCD. Introducing an estimated index comprising citrulline values and citrulline to total amino acid ratios could assure NICCD detection by NBS.
- Open Access
- 26 December 2017
- Published by MDPI AG in Preprints.org
Early Detection and Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Missed by Newborn Screening Using Tandem Mass Spectrometry
Citrullinemia is the earliest identifiable biochemical abnormality in neonates with intrahepatic cholestasis due to a citrin deficiency (NICCD) and it has been included in newborn screening panels using tandem mass spectrometry. However, only one neonate was positive among 600,000 infants born in Sapporo city and Hokkaido, Japan between 2006 and 2017. We investigated 12 neonates with NICCD who were initially considered normal in newborn mass screening (NBS) by tandem mass spectrometry, but were later diagnosed with NICCD by DNA tests. Using their initial NBS data, we examined citrulline concentrations and ratios of citrulline to total amino acids. Although their citrulline values exceeded the mean of the normal neonates and 80 % of them surpassed +3SD, all were below the cutoff of 40 nmol/mL. The ratios of citrulline to total amino acids significantly elevated in patients with NICCD compared to the control. By evaluating two indicators simultaneously, we could select about 80% of patients with missed NICCD. Introducing an estimated index comprising citrulline values and citrulline to total amino acid ratios could assure NICCD detection by NBS.
- 26 December 2017
- Published by MDPI AG in Preprints.org
Open AccessEarly Detection and Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Missed by Newborn Screening Using Tandem Mass Spectrometry
Citrullinemia is the earliest identifiable biochemical abnormality in neonates with intrahepatic cholestasis due to a citrin deficiency (NICCD) and it has been included in newborn screening panels using tandem mass spectrometry. However, only one neonate was positive among 600,000 infants born in Sapporo city and Hokkaido, Japan between 2006 and 2017. We investigated 12 neonates with NICCD who were initially considered normal in newborn mass screening (NBS) by tandem mass spectrometry, but were later diagnosed with NICCD by DNA tests. Using their initial NBS data, we examined citrulline concentrations and ratios of citrulline to total amino acids. Although their citrulline values exceeded the mean of the normal neonates and 80 % of them surpassed +3SD, all were below the cutoff of 40 nmol/mL. The ratios of citrulline to total amino acids significantly elevated in patients with NICCD compared to the control. By evaluating two indicators simultaneously, we could select about 80% of patients with missed NICCD. Introducing an estimated index comprising citrulline values and citrulline to total amino acid ratios could assure NICCD detection by NBS.
- 29 October 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (10) , 1123-1125
Immunochromatography test for rapid diagnosis of Mycoplasma pneumoniae infection
The sensitivity and specificity of a new rapid Mycoplasma pneumoniae antigen immunochromatography (IC) test, DK‐MP‐001, were determined using particle agglutination (PA) antibody response and loop‐mediated isothermal amplification (LAMP) gene detection as the gold standard. Of 165 patients, 59 were diagnosed with M. pneumoniae infection based on a ≥fourfold rise of serum PA antibody during the course of the illness. Of the first visit swabs, 60 were positive for M. pneumoniae on LAMP, and 49 were positive for M. pneumoniae antigen on IC test. Compared with PA antibody and LAMP, the sensitivity/specificity of the IC test were 81.4% (48/59) and 99.1% (105/106); and 81.7% (49/60) and 100% (105/105), respectively. IC test detected antigen in pharyngeal swabs more sensitively than in nasal swabs for the same subjects (P < 0.05). The IC test performs well enough to be used with pharyngeal swabs at the first examination.
- 29 October 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (10) , 1123-1125
Immunochromatography test for rapid diagnosis of Mycoplasma pneumoniae infection
The sensitivity and specificity of a new rapid Mycoplasma pneumoniae antigen immunochromatography (IC) test, DK‐MP‐001, were determined using particle agglutination (PA) antibody response and loop‐mediated isothermal amplification (LAMP) gene detection as the gold standard. Of 165 patients, 59 were diagnosed with M. pneumoniae infection based on a ≥fourfold rise of serum PA antibody during the course of the illness. Of the first visit swabs, 60 were positive for M. pneumoniae on LAMP, and 49 were positive for M. pneumoniae antigen on IC test. Compared with PA antibody and LAMP, the sensitivity/specificity of the IC test were 81.4% (48/59) and 99.1% (105/106); and 81.7% (49/60) and 100% (105/105), respectively. IC test detected antigen in pharyngeal swabs more sensitively than in nasal swabs for the same subjects (P < 0.05). The IC test performs well enough to be used with pharyngeal swabs at the first examination.
- 1 August 2016
- Published by Elsevier in Infant Behavior and Development
- Vol. 44, 227-239
Characteristics of antigravity spontaneous movements in preterm infants up to 3 months of corrected age
- 1 August 2016
- Published by Elsevier in Infant Behavior and Development
- Vol. 44, 227-239
Characteristics of antigravity spontaneous movements in preterm infants up to 3 months of corrected age